Key result
Beta blocker use for ≥1 year is linked to ~73% lower mortality in ovarian cancer.
Why the study?
The impact of beta blockers on survival outcomes in ovarian cancer was investigated due to unclear associations in this population.
Does beta blocker use improve survival outcomes in patients with ovarian cancer?
Cohort (n=866)
Does beta blocker use improve survival outcomes in patients with ovarian cancer?
Long-term beta blocker use (≥1 year) is associated with improved overall and disease-specific survival in patients with ovarian cancer, particularly in older patients and those with cardiovascular comorbidities.
Should not yet change practice; hypothesis-generating for long-term beta blocker use in ovarian cancer pending randomized confirmation.
OBJECTIVE: The impact of beta blockers (BBs) on survival outcomes in ovarian cancer was investigated. METHODS: By using Korean National Health Insurance Service Data, Cox proportional hazards regression was performed to analyze hazard ratios (HRs) with 95% confidence intervals (CIs) adjusting for confounding factors. RESULTS: Among 866 eligible patients, 206 (23.8%) were BB users and 660 (76.2%) were non-users. Among the 206 BB users, 151 (73.3%) were non-selective beta blocker (NSBB) users and 105 (51.0%) were selective beta blocker (SBB) users. BB use in patients aged ≥60 years, longer duration use (≥1 year), in patients with Charlson Comorbidity Index (CCI) ≥3, and in cardiovascular disease including hypertension was associated with better survival outcome. These findings were observed in both NSBB and SBB. When duration of medication was analyzed based on number of days, NSBB (≥180 days) was associated with improved overall survival (OS) with a relatively shorter period of use compared to SBB (≥720 days). In multivariate Cox proportional hazards model, longer duration of BB medication (≥1 year) was an independent favorable prognostic factor for both OS and disease-specific survival in ovarian cancer patients. CONCLUSION: In our nationwide population-based cohort study, BB use was associated with better survival outcomes in ovarian cancer in cases of long term duration of use, in older patients, and in cardiovascular and/or other underlying disease (CCI ≥3).
No takes yet. Share an insight, caveat, or question.
Baek et al. (2018) conducted a cohort in Ovarian cancer (n=866). Beta blockers vs. Non-users was evaluated on Overall survival (HR 1.046, 95% CI 0.799-1.368, p=0.745). While overall beta blocker use did not significantly affect survival, use for ≥1 year was associated with significantly improved overall survival (HR 0.266) in patients with ovarian cancer.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: